Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new prostate cancer imaging agent, 64Cu-SAR-bisPSMA, just earned the FDA's first-ever breakthrough therapy designation in PSMA PET imaging. In a head-to-head trial, it detected more than twice as many lesions as the current standard-of-care scan in men with early biochemical recurrence. Two phase 3 trials are fully enrolled, with results expected in early 2027.
The FDA has granted breakthrough therapy designation to 64Cu-SAR-bisPSMA — a next-generation radiopharmaceutical developed by Clarity Pharmaceuticals — for PET imaging of PSMA-positive lesions in prostate cancer patients with suspected biochemical recurrence (BCR). According to the company, this marks the first breakthrough therapy designation ever awarded in PSMA PET imaging, a significant milestone in a field that's become central to prostate cancer management.
The designation was backed by data from the phase 2 Co-PSMA trial, which pitted 64Cu-SAR-bisPSMA against the current standard, 68Ga-PSMA-11, in 50 patients with BCR after radical prostatectomy. The newer agent outperformed on every key metric — detecting more lesions, flagging more patients as positive, and changing planned treatment in nearly half of cases. The agent's unique design uses a cage-like chelator to keep copper-64 stable in the body, and its 12.7-hour half-life enables both same-day and next-day imaging. The same molecule can also carry copper-67 for therapy, opening the door to a theranostic approach.
By the Numbers:
Why it matters: Detecting recurrent prostate cancer early — especially at very low PSA levels — is notoriously difficult, and missed lesions can mean delayed or misdirected treatment. A scan that finds more than twice as many lesions could meaningfully shift how clinicians manage BCR, and the theranostic potential adds another layer of long-term promise.
